

# Meghna Jani

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3107505/meghna-jani-publications-by-citations.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

35  
papers

2,281  
citations

15  
h-index

47  
g-index

49  
ext. papers

2,792  
ext. citations

6.7  
avg, IF

4.41  
L-index

#	Paper	IF	Citations
35	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 960-977	7.4	1649
34	The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. <i>Rheumatology</i> , <b>2014</b> , 53, 213-22	3.9	137
33	Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 2011-9	9.5	69
32	The safety of biologic therapies in RA-associated interstitial lung disease. <i>Nature Reviews Rheumatology</i> , <b>2014</b> , 10, 284-94	8.1	54
31	High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 208-213	2.4	40
30	Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far. <i>Rheumatology</i> , <b>2018</b> , 57, 1896-1907	3.9	29
29	Social media use among young rheumatologists and basic scientists: results of an international survey by the Emerging EULAR Network (EMEUNET). <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 712-715	2.4	23
28	The Genetics of Psoriasis and Psoriatic Arthritis. <i>Journal of Rheumatology</i> , <b>2019</b> , 95, 46-50	4.1	23
27	Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. <i>RMD Open</i> , <b>2017</b> , 3, e000314	5.9	21
26	Genotyping of immune-related genetic variants identifies TYK2 as a novel associated locus for idiopathic inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1750-2	2.4	21
25	Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?. <i>Current Opinion in Rheumatology</i> , <b>2019</b> , 31, 285-292	5.3	21
24	Time trends and prescribing patterns of opioid drugs in UK primary care patients with non-cancer pain: A retrospective cohort study. <i>PLoS Medicine</i> , <b>2020</b> , 17, e1003270	11.6	20
23	Frequent discussion of insomnia and weight gain with glucocorticoid therapy: An analysis of Twitter posts. <i>Npj Digital Medicine</i> , <b>2018</b> , 1,	15.7	18
22	Cryptococcal meningitis in an HIV-negative patient with rheumatoid arthritis treated with rituximab. <i>Rheumatology</i> , <b>2011</b> , 50, 1725-7	3.9	17
21	Impact of Adverse Events Associated With Medications in the Treatment and Prevention of Rheumatoid Arthritis. <i>Clinical Therapeutics</i> , <b>2019</b> , 41, 1376-1396	3.5	15
20	Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , <b>2017</b> , 4, 309-332	4.4	15
19	Pharmacogenetics of treatment response in psoriatic arthritis. <i>Current Rheumatology Reports</i> , <b>2015</b> , 17, 44	4.9	13

18	Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. <i>Lancet, The</i> , <b>2015</b> , 385 Suppl 1, S48 <sup>40</sup>		12
17	Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels. <i>Rheumatology</i> , <b>2016</b> , 55, 2050-2055	3.9	10
16	A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice. <i>Rheumatology</i> , <b>2016</b> , 55, 2131-2137	3.9	10
15	Effectiveness of switching between biologics in psoriatic arthritis- results of a large regional survey. <i>Clinical Medicine</i> , <b>2014</b> , 14, 95-6	1.9	9
14	Annual increase in body mass index in children with asthma on higher doses of inhaled steroids. <i>Journal of Pediatrics</i> , <b>2005</b> , 147, 549-51	3.6	9
13	Latent Class Trajectory Modeling of 2-Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Disease-Modifying Antirheumatic Drugs. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1632-1642	9.5	6
12	Opioids are not just an American problem. <i>BMJ, The</i> , <b>2017</b> , 359, j5514	5.9	6
11	Twitterland: A brave new world?. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 1245-1246	2.4	6
10	Glucocorticoid use is associated with an increased risk of hypertension. <i>Rheumatology</i> , <b>2021</b> , 60, 132-139	3.9	6
9	Association of Pharmacological Biomarkers with Treatment Response and Longterm Disability in Patients with Psoriatic Arthritis: Results from OUTPASS. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 1204-1208	4.1	4
8	Abatacept in the long-term treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , <b>2012</b> , 8, 231-4	5.1	4
7	Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , <b>2021</b> , 25, 1-248	4.4	3
6	Management of the Rheumatoid Arthritis Patient with Interstitial Lung Disease. <i>Respiratory Medicine</i> , <b>2018</b> , 121-161	0.2	2
5	Opioid prescribing among new users for non-cancer pain in the USA, Canada, UK, and Taiwan: A population-based cohort study. <i>PLoS Medicine</i> , <b>2021</b> , 18, e1003829	11.6	1
4	Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider. <i>RMD Open</i> , <b>2022</b> , 8, e002216	5.9	1
3	Translating research into clinical practice: quality improvement to halve non-adherence to methotrexate. <i>Rheumatology</i> , <b>2021</b> , 60, 125-131	3.9	0
2	Unilateral breast oedema in a case of non-rheumatic giant left atrium. <i>Age and Ageing</i> , <b>2009</b> , 38, 627-8		3
1	Perceptions of opioid use and impact on quality of life in patients with musculoskeletal conditions within online health community forums. <i>Rheumatology Advances in Practice</i> , <b>2021</b> , 5, rkab078	1.1	

